← Eichor
Study identifier: NCT03750227 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

Condition: Malignant Solid Neoplasm · Metastatic Malignant Neoplasm in the Brain  ·  Sponsor: Mayo Clinic

PhasePhase 3
Planned participants140
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (4)

Mayo Clinic in ArizonaScottsdale, Arizona, United StatesRecruiting
Mayo Clinic in FloridaJacksonville, Florida, United StatesRecruiting
National Institutes of Neurological Disorders and Stroke, NIHBethesda, Maryland, United StatesRecruiting
Mayo Clinic in RochesterRochester, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03750227